Cell uptake/efflux experiments in cell culture and small animal PET imaging on tumor and inflammation models were performed. Results: Despite the low accumulation in cell culture, 18 F-FDS had good tumor uptake and contrast in the subcutaneous U87MG tumor model (4.54%ID/g at 30 min post-injection). Minimal uptake in the normal mouse brain facilitated good tumor contrast in both U87MG and GL-26 orthotopic tumor models. 18 F-FDS also had increased uptake in the inflamed foci of the TPAinduced acute inflammation model. Conclusions: Because of the ease of synthesis and favorable in vivo kinetics, 18 F-FDS may have potential applications in certain cases where FDG is inadequate (e.g., brain tumor).
Introduction

D uring the past two decades, 2-deoxy-2-[
18 F]fluoro-Dglucose (FDG) has been widely used to assess glucose uptake in patients with various diseases [1] [2] [3] [4] . Like glucose and its analog, 2-deoxyglucose, FDG is transported into the cell by specific glucose transporters and phosphorylated by the enzyme hexokinase type II. Once inside the cell, the phosphorylated tracer analog is not metabolized further. Hence, FDG is a trapped tracer, and its accumulation has the potential of tracing glucose uptake, although it cannot trace the metabolic fate of glucose inside the cell [5] .
FDG-positron emission tomography (PET) is clinically useful for detecting high-grade gliomas, cerebral lymphomas, and in some cases, unexpected brain metastases in whole-body PET examinations [6, 7] . As an adjunct to computed tomography and magnetic resonance imaging (MRI), FDG-PET can make stereotactic radiosurgery more precise in targeting primary or secondary brain cancers and can differentiate necrotic fibrosis from viable cancer tissue during follow-up in cases of abnormal or equivocal MRI results [8] . FDG-PET is effective in differentiating recurrent tumor from radiation necrosis for high-grade tumors but has limited value in defining the extent of tumor involvement and recurrence of low-grade lesions [9] . Nevertheless, normal biodistribution of FDG includes intense physiologic uptake in the brain gray matter, the highest consumer of glucose in humans. The high background, therefore, makes it difficult to detect nonphysiologic foci with elevated glucose metabolism, which may correspond to malignant lesions.
Thus, there is an urgent need to develop new PET tracers for detecting certain lesions where FDG is inadequate or fails. Unlike FDG, the introduction of 2-deoxy-2-[
18 F]fluorosorbitol ( 18 F-FDS) for imagining lesions around the brain area may be advantageous because FDS does not utilize glucose transporters, and little normal brain uptake is expected [10] . Moreover, because of the structural similarity with FDG, 18 F-FDS might be obtained from the widely available FDG by simply reducing the aldehyde group to hydroxyl group. In this report, we provided the procedure for the synthesis of 18 F-FDS and assessed this new agent in cell culture and in small animal models for its possible application in tumor and inflammation imaging around the brain area.
Materials and Methods
Materials
All chemicals were of analytical grade and were obtained commercially without further purification. Sodium borohydride (NaBH 4 ), FDG and 12-O-tetradecanoyl-phorbol-13-acetate (TPA) were purchased from Aldrich (St. Louis, MO, USA). Sep-Pak cartridges were obtained from Waters. 18 F-FDG was produced by the cyclotron team at Stanford University. 1 H NMR spectra were obtained using the INOVA-400 MHz spectrometer (Palo Alto, CA, USA) at the Chemistry Department, Stanford University. Radio thin-layer chromatography (TLC) was obtained on PeakSimple chromotography data system SRI-202. Water and all buffers were passed through Chelex 100 column before use in radiolabeling procedures to ensure heavy-metal-free conditions.
2-Deoxy-2-fluoro-sorbitol
Sodium borohydride (NaBH 4 , 10 mg, 0.265) was added to a solution of 2-deoxy-2-fluoro-D-glucose (12 mg, 0.066 mmol) in 1 ml water, and the resulting mixture was stirred at 35°C for 15 min. After quenching the reaction, the mixture was adjusted to a pH of 7.4 and filtered through an Alumina-N Sep-Pak cartridge. The filtrate showed only a single spot on silica TLC plate (R f =0.34, 80% acetonitrile with 20% water as eluent. R f =0.55 for FDG). The filtrate was lyophilized, and the title product was obtained in 
F-FDS)
NaBH 4 (2 mg, 0.053 mmol) was added to a solution of FDG (555 MBq) in saline, and the resulting mixture was stirred at 35°C for 15 min. After quenching the reaction, the mixture was adjusted to a pH of 7.4 and filtered through an Alumina-N Sep-Pak cartridge. With only one peak based on radio-TLC reader with R f =0.33 (80% acetonitrile with 20% water as eluent, R f =0.54 for FDG), 370±28 MBq (n=5) of activity was obtained. The filtrate was then reconstituted in saline and passed through a 0.22-μm Millipore filter into a sterile multidose vial for in vitro and in vivo experiments.
Cell Uptake and Efflux Assay
For the cell uptake experiment, the plastic plates (12 wells) were seeded with 8×10 5 U87MG cells/well for 16 h, and the adherent cells were then washed with glucose-free medium. FDG and 18 F-FDS were diluted in glucose-free medium (0.75 MBq/ml) and incubated with cells for 10, 15, 30, 60, and 180 min. The cell monolayer was washed three times with glucose-free medium and then lysed with NaOH-sodium dodecyl sulfate (SDS; 0.2 M NaOH, 1% SDS) for γ-counting (Packard, Meriden, CT). For the time-dependent efflux experiment, the plastic plates (12 wells) were seeded with 8×10 5 U87MG cells/well for 16 h, and the adherent cells were then washed with glucose-free medium. FDG and 18 F-FDS were diluted in glucose-free medium (0.75 MBq/ml) and then incubated with cells for 180 min. The medium was removed and recultured with glucose-free medium for 15, 30, 60, 120, and 180 min. The cell monolayer was washed with glucose-free medium three times, and the cells were lysed with NaOH-SDS (0.2 M NaOH, 1% SDS) for γ-counting. For the glucose and insulin dependence of cell uptake experiment, the plastic plates (12 wells) were seeded with 8×10 5 U87MG cells/well for 16 h, and the adherent cells were then washed with glucose-free medium. FDG and 18 F-FDS were diluted in glucose-free medium (0.75 MBq/ml) and incubated with cells for 15 min in the presence of different concentrations of glucose or insulin (0, 100, 1,000, and 2,000 μg glucose/ml medium or 0, 1, 10, and 100 μg insulin/ml). The cell monolayer was washed three times with glucose-free medium, and the cells were then lysed with NaOH-SDS (0.2 M NaOH, 1% SDS) for γ-counting.
Animal Models
Animal procedures were performed according to a protocol approved by the Stanford University Institutional Animal Care and Use Committee. The subcutaneous U87MG tumor model was generated by injection of 5×10 6 cells into the front leg of female athymic nude mice (Harlan, Indianapolis, IN, USA). The mice were used for microPET imaging studies when the tumor volume reached 200-400 mm 3 (3-4 weeks after inoculation of the cancer cells). An orthotopic U87MG human brain tumor model was obtained by intracranial injection of U87MG cells in the right frontal lobe of athymic nude mice at coordinates 2 mm lateral and 0.5 mm anterior to the bregma, and 2.5 mm intraparenchymal [11] . Each mouse was injected with 1×10 5 U87MG cells suspended in 5 μl of phosphate-buffered saline. Tumor cells were allowed to engraft for 6-7 weeks, at which point microPET imaging experiments were conducted. An orthotopic GL-26 murine glioma model was obtained by intracranial injection of GL-26 cells similar to that of the U87MG model except that C57BL/6 mice were used for the murine tumor model and subjected to microPET imaging studies 25-30 days after tumor inoculation.
To induce acute inflammation, 20 μl of TPA solution (100 μg/ml in acetone) was topically applied to the inner and outer surfaces of the right ear of BALB/c mice. Edematous ear swelling was observed after a single dose TPA challenge. The ear thickness increased from 0.24±0.01 to 0.61±0.10 mm within 6 h, at which time the mice were subjected to FDG or 18 F-FDS imaging studies.
PET Imaging and Autoradiography
PET imaging and image analysis was performed on a microPET R4 rodent model scanner (Siemens Medical Solutions USA) as described earlier [12, 13] . Each mouse was injected with about 3.7 MBq of the radiopharmaceuticals ( 18 F-FDS or FDG) under isoflurane anesthesia. For each microPET scan, 3D region of interests (ROIs) were drawn over the tumor, liver, kidneys, and muscle on decay-corrected whole-body coronal images. The average radioactivity concentration within a tumor or an organ was obtained from mean pixel values within the ROI volume, which were converted to counts per milliliter per minute by using a conversion factor. Assuming a tissue density of 1 g/ml, the counts per milliliter per minute were converted to counts per gram per minute and then For the inflammation model, autoradiography was performed using a Packard Cyclone Storage Phosphor Screen system (Downers Grove, IL, USA). The ears were harvested immediately after the microPET scans at 1 h post-injection (p.i.) for 18 F-FDS or 18 F-FDG. After measuring the radioactivity of each ear with a γ-counter (Packard), the ears were taped to a chilled autoradiography cassette containing a super resolution screen (Packard) and stored overnight at −20°C. Screens were laser-scanned with the Packard Cyclone.
Statistical Analysis
Quantitative data were expressed as mean ± SD. Means were compared using one-way analysis of variance and Student's t test. P values G0.05 were considered statistically significant.
Results
Chemistry and Radiochemistry
Cold FDS was obtained through the reduction of cold FDG (Fig. 1) . The same method to reduce FDG also provided 18 F-FDS in high yield. No unreacted FDG or other side product was observed. The radio-TLC result correlated well with the cold reaction TLC stained with KMnO 4 (under the same TLC strip, the cold compound had R f =0.34, and the radio peak gave R f = 0.33). The total synthesis time of 
Cell Uptake and Efflux Assay
In the cell uptake experiment, 18 F-FDS behaved very differently from FDG (Fig. 2a) . 18 F-FDS had only 0.1% uptake in U87MG cells compared with up to 40% cell uptake for FDG. Moreover, FDG had a lower efflux percentage especially at early time points, whereas the efflux for 18 F-FDS flattened quickly (Fig. 2b) . We also found that the cell uptake of 18 F-FDS was not dependent on the concentration of glucose or insulin (Fig. 2c, d ). FDG uptake, on the other hand, was significantly decreased with glucose competition and increased with insulin (data not shown). Based on these cell uptake and efflux results, we propose that, unlike FDG, 18 F-FDS may not be involved in metabolic pathway or otherwise significantly taken up by cells because of the low cell uptake and little retention of the radioactivity.
Small Animal PET Imaging of Tumor-Bearing Mice and Inflammation Mice
Dynamic microPET scans were first performed on the subcutaneous U87MG xenograft model, and selected coronal images at different time points after injection of 18 F-FDS were shown in Fig. 3a . The tumor was clearly visible with high contrast to contralateral background as early as 5 min p.i. Quantitation of tumor and major organ activity accumulation in microPET scans was performed by measuring ROIs encompassing the entire tumor and organs in the coronal orientation. The U87MG tumor uptake of 18 F-FDS was calculated to be 2.43%ID/g at 15 min p.i. in this animal model. The tumor to major organ ratios were also calculated at 30 min p.i., and the results were shown in Fig. 3b . The high tumor to brain ratio (up to 13.6) made 18 F-FDS a promising tracer for detecting lesions around brain area.
Representative microPET images of the orthotopic U87MG tumor model at different time points after 18 F-FDS injection were shown in Fig. 4a . Because of the low background activity of normal brain, 18 F-FDS uptake within the tumor area was low but could be differentiated from the normal brain. In comparison, 18 F-FDG showed high uptake in both normal and tumor-bearing mouse brains (Fig. 4b) , which limited its ability to delineate the tumor. We also compared 18 F-FDS with FDG in the orthotopic GL-26 tumor model (Fig. 4c) . Unlike FDG, the tumor could be clearly viewed by 18 F-FDS, and the uptake could be as high as 6.38%ID/g at 40 min. Similar to U87MG model, FDG is unable to separate the high normal brain uptake from the tumor in GL-26 tumor mice. 18 F-FDS is cleared more slowly in this GL-26 tumor model because a 60-min dynamic scan was carried out. 18 F-FDS was also successful in visualizing the TPAinduced inflammation model (Fig. 5a) . The tracer uptake in the inflamed ear was four times higher than the control ear based on γ-counting results (Fig. 5c ). Both 18 F-FDS and FDG gave good inflamed ear to normal ear ratios on autoradiography (Fig. 5b) and gamma-counting (Fig. 5c) , although the absolute uptake for 18 F-FDS was only one fifth of that for FDG. However, the inflamed ear was harder to detect for FDG on microPET because of high brain activity (Fig. 5a ).
Discussion
FDG-PET has been shown to effectively detect many types of primary tumors and metastases. However, it has a limited role in the diagnosis of prostate cancer and brain tumors because of the high background. In our experimental settings, we found that 18 F-FDS, a PET tracer obtained by reducing FDG with NaBH 4 , has good tumor to background ratios in both subcutaneous nonbrain regions and orthotopic brain tumor xenograft models. This tracer might also be useful for detecting inflammation near brain area.
The aldose reductase sorbitol (ARS) pathway [14] consists of two enzymes, aldose reductase (ALR) and sorbitol dehydrogenase (SDH): [15] . A recent study on the catalysis mechanism of these enzymes showed that ALR (first step) has broad substrate specificity, and FDG is a good substrate for it [10] . In contrast, SDH has a more discriminating pattern of substrate specificity (second step). The 2-hydroxyl group of sorbitol is a critical functional group that acts as a hydrogen bond donor to an active site of SDH [15] . FDS, with substitution by fluorine at the 2-position of Dglucitol, completely abrogated the recognition by SDH [10, 16] . Our cell uptake and efflux studies also support the observations by the 19 F-NMR spectroscopy and enzymatic assays described above.
Intracellular accumulation of FDG is mediated by two different mechanisms: transport and endocytosis [17] . The fact that cellular uptake of FDG is effectively inhibited in the presence of high concentrations of glucose suggests its transport into brain tumor cells via specific glucose transport proteins. On the other hand, 18 F-FDS exhibited very poor diffusion into cells and low intracellular retention (Fig. 2a) . Because the 2-position of sorbitol was substituted by 18 F, SDH-mediated retention of 18 F-FDS is likely abrogated in U87MG tumor cells. Without the trapping mechanism found for cell retention, cellular uptake of 18 F-FDS might be based on passive diffusion and, thereby, driven by the concentration gradient between extra-and intracellular compartments. Because of the hydrophilic character of 18 F-FDS, it does not penetrate the plasma membrane and is, thus, not retained in the cell.
Despite the low cellular uptake of 18 F-FDS in culture, this tracer showed good tumor/muscle contrast in the subcutaneous U87MG tumor model. The U87MG cell uptake of 18 F-FDS in culture is about two log orders of magnitude lower than that of 18 F-FDG; whereas the U87MG tumor uptake of 18 F-FDS in subcutaneous U87MG xenograft model is only three-to fourfold lower than that of FDG. It is also of note that the tumor uptake of FDG increases, whereas that of 18 F-FDS decreases with time. All these observations suggest that 18 F-FDS has the characteristics of a blood flow agent [18, 19] . And if this is true, the tumor contrast resulting from 18 F-FDS imaging is more likely attributed to the accumulation of tracer in the interstitial tumor space (in the extracellular fluid or in the blood that has found its way into the interstitial space because of leaky vasculature). However, more assays or measures for 18 F-FDS metabolites need to be carried out to further understand the tracer before a conclusion is drawn. We also tested the relative rates of excretion of 18 F-FDS and FDG into the urinary bladder. The activity concentration in urine was determined to be 38.2±6.9 mBq/g for 18 The most striking difference between FDG and 18 F-FDS in vivo is the behavior in orthotopic brain tumor models. Although both tracers have good hydrophilicity and small molecular weight, FDG exhibits high and persistent uptake in the normal mouse brain, whereas 18 F-FDS has virtually no uptake in normal brain. FDG was unable to differentiate tumor from normal brain in both orthotopic U87MG and GL-26 tumor models. 18 F-FDS, however, shows excellent tumor/brain contrast as the brain had minimal activity accumulation. Whether such finding can be translated into clinic for imaging brain tumor patients has yet to be determined. FDG is not a cancer-specific agent and is known to accumulate in cases of acute inflammation in granulomatous diseases and in autoimmune diseases [20] [21] [22] . Under such conditions, the suggestion is that 18 F-FDG is taken up by infiltrating cells such as macrophages, lymphocytes, and granulocytes. In our TPA-induced acute inflammation model, 18 F-FDG showed markedly increased uptake in TPA-treated mouse ear as compared to the untreated control ear, presumably because of the uptake by infiltrating macrophages. Similar contrast (but lower absolute uptake) was also observed for 18 F-FDS. However, the mechanism for the inflammation contrast derived from 18 F-FDS could be very different from FDG. Acute inflammation causes vessel dilation and, thus, increased blood flow to the areas of inflammation. Increased blood flow and leaky vasculature might allow 18 F-FDS to escape the bloodstream and enter inflamed tissues; the net result may lead to increased uptake of 18 F-FDS by the inflamed foci.
Although we have demonstrated that 18 F-FDS can be efficiently obtained and applied for imaging brain tumor and inflammation in mice, it is still not confirmative how the 18 F-FDS transport across the blood-brain barrier and tumor cell membranes, as well as the mechanism of 18 F-FDS for brain tumor imaging. More assays and measures for 18 F-FDS metabolites in tumor, brain blood, or urine will be needed in the future to help understand the mechanism for the uptake of this compound in vivo.
Conclusions
We successfully synthesized 18 F-FDS by reducing FDG. 18 F-FDS, lacking appropriate transporters and/or enzymes for specific cell uptake and retention, has been applied to image brain tumor and inflammation in mice. 18 F-FDS, with low uptake in the normal brain, might be suitable for glioma imaging. The robustness of the tracer synthesis starting from readily available FDG, as well as excellent brain tumor imaging characteristics, warrants further testing of this new compound in preclinical and eventually clinical applications.
